Cargando…

Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature

SIMPLE SUMMARY: Breast cancer is a leading cause of female cancer-related death worldwide. Anti-HER2-targeted therapies dramatically improved prognosis for HER2-positive breast cancer patients. Despite that, growing drug resistance due to the pressure of therapy is relatively frequent. For that reas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isca, Chrystel, Piacentini, Federico, Mastrolia, Ilenia, Masciale, Valentina, Caggia, Federica, Toss, Angela, Piombino, Claudia, Moscetti, Luca, Barbolini, Monica, Maur, Michela, Dominici, Massimo, Omarini, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508299/ https://www.ncbi.nlm.nih.gov/pubmed/34638377 http://dx.doi.org/10.3390/cancers13194894

Ejemplares similares

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
por: Omarini, Claudia, et al.
Publicado: (2020)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2020)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
por: Omarini, Claudia, et al.
Publicado: (2022)

The Role of Exosomes in Breast Cancer Diagnosis
por: Piombino, Claudia, et al.
Publicado: (2021)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
por: Toss, Angela, et al.
Publicado: (2022)

Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review
por: Canino, Fabio, et al.
Publicado: (2022)

Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2019)

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges
por: Cerma, Krisida, et al.
Publicado: (2023)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
por: Omarini, Claudia, et al.
Publicado: (2020)

Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence
por: Aramini, Beatrice, et al.
Publicado: (2022)

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
por: Omarini, Claudia, et al.
Publicado: (2018)

Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe
por: Moscetti, L., et al.
Publicado: (2021)

Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it!
por: Omarini, Claudia, et al.
Publicado: (2020)

Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era
por: Toss, A., et al.
Publicado: (2021)

Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review
por: Maur, Michela, et al.
Publicado: (2017)

Personalized Systemic Therapies in Hereditary Cancer Syndromes
por: Mastrodomenico, Luciana, et al.
Publicado: (2023)

Chasing the Role of miRNAs in RCC: From Free-Circulating to Extracellular-Vesicle-Derived Biomarkers
por: Mastrolia, Ilenia, et al.
Publicado: (2023)

Management of PALB2‐associated breast cancer: A literature review and case report
por: Toss, Angela, et al.
Publicado: (2023)

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
por: Omarini, Claudia, et al.
Publicado: (2018)

Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
por: Toss, Angela, et al.
Publicado: (2021)

Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
por: Venturelli, Marta, et al.
Publicado: (2018)

Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications
por: Toss, Angela, et al.
Publicado: (2018)

Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?
por: Cortesi, Laura, et al.
Publicado: (2021)

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations
por: Guaitoli, Giorgia, et al.
Publicado: (2021)

Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma
por: Maur, Michela, et al.
Publicado: (2015)

Are you treating ypN0 patient with adjuvant abemaciclib?
por: Toss, A., et al.
Publicado: (2023)

GD2 expression in breast cancer
por: Orsi, Giulia, et al.
Publicado: (2017)

Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study
por: Isca, Chrystel, et al.
Publicado: (2022)

Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study
por: Toss, Angela, et al.
Publicado: (2021)

Lifestyle Intervention on Body Weight and Physical Activity in Patients with Breast Cancer Can Reduce the Risk of Death in Obese Women: The EMILI Study
por: Cortesi, Laura, et al.
Publicado: (2020)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA
por: Piombino, Claudia, et al.
Publicado: (2020)

Arming Mesenchymal Stromal/Stem Cells Against Cancer: Has the Time Come?
por: Golinelli, Giulia, et al.
Publicado: (2020)

Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2021)

Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2022)

Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study
por: Fabbri, Agnese, et al.
Publicado: (2023)

Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges
por: Stucci, Luigia Stefania, et al.
Publicado: (2022)

Human Mesenchymal Stem Cell Combined with a New Strontium-Enriched Bioactive Glass: An ex-vivo Model for Bone Regeneration
por: Bellucci, Devis, et al.
Publicado: (2019)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9hlkigo4f38cv0bfl5of9ht08m